Bristol-Myers Squibb Company (BMY) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - General

Earnings Reports

• Bristol-Myers Squibb (BMY) Q2 2026: Growth Portfolio Now 60% of Sales, Pipeline Readouts Poised to Reshape Long-Term Trajectory
  July 30, 2026
• Bristol-Myers Squibb (BMY) Q4 2025: Growth Portfolio Hits 60% of Revenue as Legacy Step-Down Looms
  June 15, 2026
• Bristol-Myers Squibb (BMY) Q1 2026: Growth Portfolio Climbs 9% as Pipeline Readouts Set Stage for Second-Half Inflection
  April 30, 2026
• Bristol Myers Squibb (BMY) Q3 2025: Growth Portfolio Up 17% as Pipeline Catalysts Accelerate
  October 30, 2025
• Bristol-Myers Squibb (BMY) Q2 2025: Growth Portfolio Jumps 17% as Pipeline and Partnerships Recast Trajectory
  July 31, 2025
• Bristol-Myers Squibb (BMY) Q1 2025: Growth Portfolio Climbs 18% as Pipeline Readouts Set Stage for Decade-End Reacceleration
  July 01, 2025
• Bristol-Myers Squibb (BMY) Q3 2024: Growth Portfolio Hits 50% of Sales as Neuroscience Launch Reshapes Outlook
  October 31, 2024
• Bristol Myers Squibb (BMY) Q2 2024: Growth Portfolio Now 46% of Sales, Pipeline Catalysts Build Into 2025
  July 26, 2024
• Bristol-Myers Squibb (BMY) Q1 2024: Growth Portfolio Hits 40% of Revenue as $1.5B Cost Reset Accelerates Pipeline Focus
  April 25, 2024
• Bristol-Myers Squibb (BMY) Q4 2023: Growth Portfolio Delivers 15% Expansion, Offsetting Legacy Erosion
  February 02, 2024

Browse all companies